{"article_title": "A Sense of D\u00e9j\u00e0 Vu: The Debate Surrounding State Biosimilar Substitution Laws", "article_keywords": ["biosimilars", "dj", "versions", "generic", "similarities", "sense", "legislation", "savings", "pathway", "traditional", "surrounding", "state", "vu", "substitution", "report", "biosimilar", "debate", "laws"], "article_url": "http://www.aarp.org/health/health-insurance/info-2014/the-debate-surrounding-state-biosimilar-laws-AARP-ppi-health.html", "article_text": "The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics. This Insight on the Issues discusses controversial new state legislation that could greatly limit the savings from biosimilars and notes similarities to the debate ignited by the passage of federal legislation that encouraged the development of traditional generic drugs.\n\nRead This Report", "article_metadata": {"DivisionMain": "Division:Public Policy Institute#Health Care#Prescription Drugs", "Division1": "Division:Public Policy Institute#Health Care#Prescription Drugs", "page_title": "A Sense of D\u00e9j\u00e0 Vu: The Debate Surrounding State Biosimilar Substitution Laws", "estimated_publish_date": "2016-01-29", "Last-Modified": "2014-09-18T15:17:12.563-04:00", "keywords": "health care, health spending, biologics, biosimilars, state legislation, prescription drugs, prescription drug costs", "paywallStatus": "off", "livefyreId": "350119:http://www.aarp.org/health/health-insurance/info-2014/the-debate-surrounding-state-biosimilar-laws-AARP-ppi-health.html", "author": "Leigh Purvis, PPI Health Team", "lfdataConfig": "{\"globalConfig\":{\"network\":\"aarp.fyre.co\"},\"livefyreConfig\":[{\"collectionMeta\":\"eyJhbGciOiJIUzI1NiJ9.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.M3-hZLKiQUqVXSsb5r1jjaoLpoJ2xkLcyED-48xPn-Q\",\"checksum\":\"3bc5b05c566b6a29a9162149b107d306\",\"siteId\":\"350139\",\"articleId\":\"http://www.aarp.org/health/health-insurance/info-2014/the-debate-surrounding-state-biosimilar-laws-AARP-ppi-health.html\",\"el\":\"livefyreConversation\",\"disableAvatars\":true,\"postToButtons\":[\"tw\",\"fb\"]}]}", "comments": "on", "source": "ppi", "type": "info", "description": "The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics.", "robots": "index,follow", "Subject1": "DCSubjects:Health", "Subject2": "DCSubjects:Health/Health Insurance/Health Care Reform", "DivisionCategory2": "Prescription Drugs", "DivisionCategory1": "Health Care", "language": "english", "og": {"site_name": "AARP", "description": "The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics.", "title": "A Sense of D\u00e9j\u00e0 Vu: The Debate Surrounding State Biosimilar Substitution Laws - AARP", "url": "http://www.aarp.org/health/health-insurance/info-2014/the-debate-surrounding-state-biosimilar-laws-AARP-ppi-health.html", "image": "http://cdn.aarp.net/etc/aarp/statics/global/img/logos/aarp_50x50.imgcache.rev1463067051643.png", "type": "article"}, "contentId": "/content/aarp/en/home/health/health-insurance/info-2014/the-debate-surrounding-state-biosimilar-laws-AARP-ppi-health", "mcafeesecure-site-verification": "fa79d1a3c2770869e1286a81816d01a4", "fb": {"app_id": 114175878660191}, "IALevel1": "health", "IALevel2": "health-insurance", "s43": "2a.AffordableCareAct|MyHealth", "action": "read", "dateToday": "2016-05-25"}, "_id": "\"57477af46914bd0286fdfdea\"", "article_summary": "The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics.\nThis Insight on the Issues discusses controversial new state legislation that could greatly limit the savings from biosimilars and notes similarities to the debate ignited by the passage of federal legislation that encouraged the development of traditional generic drugs.\nRead This Report"}